What is the standard targeted therapy regimen for a child or adolescent with high‑risk neuroblastoma, including anti‑GD2 immunotherapy (dinutuximab), granulocyte‑macrophage colony‑stimulating factor (GM‑CSF), interleukin‑2 (IL‑2), isotretinoin, and what options are recommended for anaplastic lymphoma kinase (ALK)‑mutated or relapsed/refractory disease such as crizotinib, lorlatinib, or high‑dose iodine‑131‑metaiodobenzylguanidine (I‑131‑MIBG) therapy?

Neuroblastoma Targeted Therapy

For high-risk neuroblastoma, the standard targeted therapy regimen is dinutuximab (anti-GD2 antibody) combined with GM-CSF and isotretinoin, administered for 5 cycles following consolidation therapy, with IL-2 no longer recommended due to lack of benefit and increased toxicity. 1, 2

Standard Post-Consolidation Immunotherapy Regimen

The NCCN 2024 guidelines provide a Category 1 recommendation for anti-GD2 antibody therapy following induction and consolidation treatment 1:

Core Components (FDA-Approved)

• Dinutuximab: 17.5 mg/m²/day IV infusion over 10-20 hours for 4 consecutive days per cycle 2
• GM-CSF (sargramostim): Given during cycles 1,3, and 5 1, 2
• Isotretinoin: Administered for 6 cycles as a differentiating agent 1
• Total duration: 5 cycles of immunotherapy 1

Critical Update: IL-2 No Longer Recommended

Interleukin-2 is no longer included in standard protocols based on the SIOPEN HR-NBL1 trial, which demonstrated that IL-2 did not improve outcomes and significantly increased toxicity 1. COG high-risk protocols have eliminated IL-2, and the NCCN panel endorses this approach 1.

Required Supportive Care

Pain Management (Mandatory)

• Morphine sulfate: 50 mcg/kg IV bolus immediately before dinutuximab, then continuous infusion at 20-50 mcg/kg/hour during and for 2 hours after completion 2
• Additional boluses of 25-50 mcg/kg every 2 hours as needed
• Consider gabapentin or lidocaine if opioids inadequate 2

Premedication Protocol

• Hydration: 0.9% NaCl 10 mL/kg IV over 1 hour before each infusion 2
• Antihistamine: Diphenhydramine 0.5-1 mg/kg (max 50 mg) IV 20 minutes prior 2
• Antipyretics: Acetaminophen 10-15 mg/kg (max 650 mg) 20 minutes prior 2

Continuation Therapy Option

Eflornithine received FDA approval in December 2023 as continuation therapy for patients achieving partial response or better after completing anti-GD2 immunotherapy 1:

• Dose: 750 mg/m² ± 250 mg/m² orally twice daily for up to 2 years
• Evidence: Study 3b showed improved outcomes (EFS HR 0.48, OS HR 0.32) compared to historical controls 1
• NCCN Category 2B recommendation - discuss with families as an option 1
• Key toxicity: Monitor hearing closely (audiograms/BAER) due to risk of hearing loss 1

ALK-Mutated Neuroblastoma

For patients with ALK-driven disease (mutations or amplifications):

Relapsed/Refractory Setting

Lorlatinib is the preferred ALK inhibitor based on phase 1 trial data 3:

• Pediatric RP2D: 115 mg/m² daily 3
• Adult RP2D: 150 mg daily 3
• Response rates: 30% in children as monotherapy, 63% when combined with topotecan/cyclophosphamide 3
• Key advantage: Overcomes crizotinib resistance 3
• Manageable toxicities: Hypertriglyceridemia (90%), hypercholesterolemia (79%), weight gain (87%); neurobehavioral effects mainly in adults, resolve with dose adjustment 3

Crizotinib

• Less effective due to clinical resistance in neuroblastoma despite ALK mutations 3
• Lorlatinib demonstrates superior activity 3

Relapsed/Refractory Disease Options

I-131-MIBG Therapy

• Reserved for MIBG-avid relapsed/refractory disease
• Used when standard therapies have failed
• Requires adequate bone marrow reserve

Chemoimmunotherapy Combinations

For progressive disease after consolidation, the NCCN recommends chemoimmunotherapy or clinical trial enrollment 1. Recent data suggest:

• Extended dinutuximab beta cycles (>5 cycles) with chemotherapy show improved responses in relapsed/refractory patients 4
• 38.5% of patients achieved best response beyond standard 5 cycles 4
• 2-year PFS: 83.2%, 2-year OS: 94.7% 4

Treatment Algorithm Summary

1. After achieving ≥PR following induction/consolidation: Start dinutuximab + GM-CSF + isotretinoin (5 cycles)
2. If ALK-mutated and relapsed/refractory: Add lorlatinib 115 mg/m² daily
3. After completing immunotherapy with ≥PR: Consider eflornithine continuation for 2 years
4. If progressive during/after immunotherapy: Chemoimmunotherapy combinations or clinical trial
5. Monitor closely: Hearing (audiograms), cardiac function (echo/ECG), renal function (GFR), pain control

Critical Pitfalls to Avoid

• Do not use IL-2 - increases toxicity without survival benefit 1
• Never skip pain premedication - severe neuropathic pain occurs in majority of patients; inadequate analgesia is the most common reason for treatment interruption 2
• Monitor for infusion reactions - occur in 26% of patients; have emergency medications ready 2
• Verify adequate organ function before each cycle - hematologic, respiratory, hepatic, and renal function must be adequate 2
• Hearing surveillance is mandatory - ototoxicity is cumulative and occurs at critical age for language development 1